About: Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan
Creator	Suzuki, Motoi Aoshima, Masahiro Katsurada, Naoko Morimoto, Konosuke Yaegashi, Makito Hosokawa, Naoto Kaneko, Norihiro Otsuka, Yoshihito Le, Minh Yoshida, Lay
Source	Elsevier; Medline; PMC
abstract	Abstract Background The effectiveness of inactivated influenza vaccine (IIV) against laboratory-confirmed influenza pneumonia in older adults remains to be established. Methods Pneumonia patients aged ≥65 years who visited a study hospital in Chiba, Japan, were prospectively enrolled from February 2012 to January 2014. Sputum samples were collected from participants and tested for influenza virus by polymerase chain reaction assays. Influenza vaccine effectiveness (IVE) against laboratory-confirmed influenza pneumonia was estimated by a test-negative design. Results Among a total of 814 pneumonia patients, 42 (5.2%) tested positive for influenza: 40 were positive for influenza A virus, and two were positive for influenza B virus. The IVE against laboratory-confirmed influenza pneumonia was 58.3% (95% confidence interval, 28.8–75.6%). The IVE against influenza pneumonia hospital admission, severe pneumonia, and death was 60.2% (95% CI, 22.8–79.4%), 65.5% (95% CI, 44.3–78.7%), and 71% (95% CI, −62.9% to 94.8%), respectively. In the subgroup analyses, the IVE against influenza pneumonia was higher for patients with immunosuppressive conditions (85.9%; 95% CI, 67.4–93.9%) than for those without (48.7%; 95% CI, 2.7–73%) but did not differ by patients’ statin use status. Conclusion IIV effectively reduces the risk of laboratory-confirmed influenza pneumonia in older adults.
has issue date	2018-05-17(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2018.04.037
bibo:pmid	29685596
has license	els-covid
sha1sum (hex)	f3c1cf5ea0a23423b15f6cc24d1498d85ba1b518
schema:url	https://doi.org/10.1016/j.vaccine.2018.04.037
resource representing a document's title	Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan
has PubMed Central identifier	PMC7126450
has PubMed identifier	29685596
schema:publication	Vaccine
resource representing a document's body	covid:f3c1cf5ea0a23423b15f6cc24d1498d85ba1b518#body_text
is schema:about of	named entity 'effectiveness' named entity 'influenza' named entity 'influenza A virus' named entity 'prospectively' named entity 'subgroup analyses' named entity 'influenza' named entity 'laboratory' named entity 'Effectiveness' named entity 'CONFIRMED' named entity 'DESIGN' named entity 'SEVERE PNEUMONIA' named entity 'POLYMERASE CHAIN REACTION' named entity 'TESTED FOR' named entity 'TOTAL' named entity 'NEGATIVE' named entity 'CONCLUSION' named entity 'BACKGROUND' named entity 'INACTIVATED INFLUENZA VACCINE' named entity 'METHODS' named entity 'JAPAN' named entity 'STATUS' named entity 'STUDY' named entity 'COLLECTED' named entity 'INFLUENZA VIRUS' named entity 'PNEUMONIA' named entity 'CONFIDENCE INTERVAL' named entity 'IMMUNOSUPPRESSIVE' named entity 'CHIBA' named entity 'INFLUENZA PNEUMONIA' named entity 'PARTICIPANTS' named entity 'HOSPITAL' named entity 'INFLUENZA B VIRUS' named entity 'LABORATORY' named entity 'HIGHER' named entity 'POSITIVE FOR' named entity 'LABORATORY' named entity 'EFFECTIVENESS' named entity 'ESTABLISHED' named entity 'YEARS' named entity 'VACCINE EFFECTIVENESS' named entity 'IVE' named entity 'RESULTS' named entity 'BUT' named entity 'INFLUENZA A VIRUS' named entity 'YEARS' named entity 'AGED' named entity 'TEST' named entity 'DID' named entity 'JAPAN' named entity 'INACTIVATED INFLUENZA VACCINE' named entity '2.7' named entity 'ENROLLED' named entity 'AGED' named entity 'JANUARY' named entity 'INFLUENZA' named entity 'FEBRUARY' named entity 'SPUTUM' named entity 'SAMPLES' named entity 'DEATH' named entity 'CONFIRMED' named entity 'CONDITIONS' named entity 'SUBGROUP' named entity 'EFFECTIVENESS' named entity 'ADULTS' named entity 'INFLUENZA PNEUMONIA' named entity 'STATIN' named entity 'INFLUENZA VACCINE' named entity 'RISK OF' named entity 'USE' named entity 'HOSPITAL ADMISSION' named entity 'ESTIMATED' named entity 'PATIENTS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software